TVRD
Tvardi Therapeutics, Inc.
$3.28
-0.52 (-13.68%)
At close · Jul 10
Market Cap
$30.77M
Shares
9,381,344
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$7.14M
-66%
FY2024
Net Income
-$18.21M
+38%
FY2025
Gross Margin
100%
FY2021
Operating Margin
-393.82%
+185.6pp
FY2024
Diluted EPS
-$3.26
+71.5%
FY2025
Operating Cash Flow
-$23.5M
-28.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7.57M | — | $7.14M | $20.97M | $41.87M | $23.03M | $135.08M | $19.89M | $13.47M | $911K | $86K | $3.8M | $3.18M | $11.96M | $1.19M | |
| — | — | — | — | — | $0 | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $23.03M | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | 100% | — | — | — | — | — | — | — | — | — | |
| $19.81M | $18.01M | $23.65M | $108.51M | $91.88M | $82.7M | $107.85M | $113.82M | $75.53M | $48.52M | $49.25M | $21.22M | $15.07M | $8.69M | $4.6M | |
| $9.63M | $8.74M | $4.46M | $27.78M | $30.26M | $29.41M | $21.85M | $17.75M | $15.32M | $11.87M | $9.23M | $7.77M | $6.18M | $3.52M | $2.83M | |
| — | $95K | $95K | $259K | $248K | $248K | $209K | $198K | $370K | $495K | $1.47M | $839K | $783K | $789K | $1.02M | |
| $3.16M | — | $5.57M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $29.45M | $26.75M | $28.11M | $142.46M | $129.4M | $112.11M | $129.7M | $131.57M | $90.85M | $60.4M | $58.49M | $28.99M | $21.25M | $12.2M | $7.43M | |
| -$29.45M | -$26.75M | -$28.11M | -$121.5M | -$87.54M | -$89.08M | $5.39M | -$111.68M | -$77.38M | -$59.49M | -$58.4M | -$25.19M | -$18.07M | -$237K | -$6.24M | |
| — | — | -393.82% | -579.43% | -209.08% | -386.85% | 3.99% | -561.6% | -574.52% | -6529.64% | -67906.98% | -662.32% | -568.84% | -1.98% | -524.03% | |
| — | -$26.65M | -$28.01M | -$121.24M | -$87.29M | -$88.84M | $5.59M | -$111.48M | -$77.01M | -$58.99M | -$56.94M | -$24.35M | -$17.29M | $552K | -$5.22M | |
| — | $700K | $700K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $7.16M | -$2.04M | $3.59M | $2.06M | $642K | $2.33M | $4.49M | $2.98M | $1.16M | $652K | $101K | $126K | -$3.76M | — | |
| — | — | -$71.27M | -$118.51M | -$85.47M | -$88.44M | $7.72M | -$107.19M | -$74.4M | -$58.33M | -$57.75M | -$25.09M | -$17.95M | -$3.99M | -$6.3M | |
| — | $0 | $0 | $0 | $0 | $0 | -$691K | -$816K | -$389K | -$204K | -$468K | -$397K | -$201K | -$30K | -$31K | |
| -$15.44M | -$18.21M | -$29.4M | -$118.51M | -$85.47M | -$88.44M | $8.41M | -$106.37M | -$74.01M | -$58.13M | -$57.28M | -$24.69M | -$17.75M | -$3.96M | -$6.27M | |
| — | — | -411.9% | -565.21% | -204.16% | -384.06% | 6.23% | -534.91% | -549.51% | -6380.35% | -66604.65% | -649.22% | -558.55% | -33.12% | -526.97% | |
| -$15.44M | -$18.21M | -$29.4M | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$15.44M | -$18.21M | -$29.4M | -$117.1M | -$86.79M | -$88.87M | $8.31M | -$106.09M | -$74.06M | -$58.2M | -$57.24M | -$24.73M | -$17.75M | -$3.07M | — | |
| USD/shares | — | -$2.46 | -$11.42 | -$78.78 | -$57.36 | -$62.64 | $6.48 | -$89.64 | -$74.16 | — | — | — | — | — | — |
| USD/shares | — | -$3.26 | -$11.42 | -$78.78 | -$57.36 | -$62.64 | $6.48 | -$89.64 | -$74.16 | — | — | — | — | — | — |
| shares | — | 7.42M | 2.57M | 1.5M | 1.49M | 1.41M | 1.32M | 1.19M | 997.02K | 866.75K | 757.75K | 683.9K | 582.39K | 114.81K | 91.67K |
| shares | — | 7.78M | 2.57M | 1.5M | 1.49M | 1.41M | 1.33M | 1.19M | 997.02K | 866.75K | 757.75K | 683.9K | 582.39K | 114.81K | 91.67K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.68×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|
| Other Revenue | $4,327,000 | $699,000 | — | — | — | — | — |
| Other Revenue Noncash | $4,327,000 | $699,000 | — | — | — | — | — |
| Collaborative Revenue | $2,086,000 | $12,936,000 | $16,572,000 | $706,000 | — | — | — |
| Commercial Supply Revenue | $640,000 | $5,843,000 | $10,223,000 | $701,000 | — | — | — |
| Clinical Compound Revenue | $84,000 | $165,000 | — | $398,000 | $643,000 | $140,000 | $33,000 |
| License and Milestone Fees | — | $910,000 | $15,000,000 | $21,223,000 | $134,439,000 | $19,746,000 | $13,436,000 |
| Royalty | — | $415,000 | $72,000 | — | — | — | — |